Results from the primary analysis of the Phase III study showed that 77% of treatment-experienced HIV-1 infected adults taking Prezista (darunavir) 600mg tablets with 100mg Prezista/r (ritonavir) twice daily, plus an optimized background regimen of antiretroviral agents (ARV), reached a plasma viral load of